DONALD E. BOBO JR - 05 May 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP,Strategy/Corp Development
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 05 May 2023
Transactions value $: -$886,929
Form type: 4
Filing time: 08 May 2023, 21:54:11 UTC
Previous filing: 04 May 2023
Next filing: 11 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Sale	-$499K	-5.64K	-9.11%	$88.63	56.2K	05 May 2023	Direct
transaction	EW	Common Stock	Options Exercise	$0	+4.77K	+8.48%	$0.00	61K	07 May 2023	Direct	F1
transaction	EW	Common Stock	Tax liability	-$263K	-2.97K	-4.87%	$88.74	58K	07 May 2023	Direct
transaction	EW	Common Stock	Tax liability	-$124K	-1.4K	-2.41%	$88.74	56.6K	08 May 2023	Direct
holding	EW	Common Stock						38.4K	05 May 2023	401(k)
holding	EW	Common Stock						112K	05 May 2023	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Performance Rights	Options Exercise	$0	-4.77K	-78.47%	$0.00	1.31K	07 May 2023	Common Stock	4.77K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

Content

On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.